![Sylvie le Gledic](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Sylvie le Gledic
Plus aucun poste en cours
Historique de carrière de Sylvie le Gledic
Anciens postes connus de Sylvie le Gledic
Sociétés | Poste | Début | Fin |
---|---|---|---|
BioSystems International SAS
![]() BioSystems International SAS BiotechnologyHealth Technology Biosystems International is a biotechnology company engaged in protein biomarker R&D using a unique and proprietary monoclonal antibody based proteomics technology (mAb proteomics), leading to the development of: Novel blood-based diagnostics for cancer and chronic diseases through the use of its innovative mAb proteomics approach, BSI is poised to translate its discoveries into novel blood-based diagnostics products for the early detection of cancer, a number of chronic diseases, and cancer recurrence with its most advanced program in the area of lung cancer currently under development. | Conseiller Juridique Général | 02/12/2009 | 06/03/2014 |
Formation de Sylvie le Gledic
Université Paris 1 Panthéon-Sorbonne | Doctorate Degree |
Statistiques
Internationale
France | 3 |
Opérationnelle
General Counsel | 1 |
Doctorate Degree | 1 |
Sectorielle
Health Technology | 2 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 1 |
---|---|
BioSystems International SAS
![]() BioSystems International SAS BiotechnologyHealth Technology Biosystems International is a biotechnology company engaged in protein biomarker R&D using a unique and proprietary monoclonal antibody based proteomics technology (mAb proteomics), leading to the development of: Novel blood-based diagnostics for cancer and chronic diseases through the use of its innovative mAb proteomics approach, BSI is poised to translate its discoveries into novel blood-based diagnostics products for the early detection of cancer, a number of chronic diseases, and cancer recurrence with its most advanced program in the area of lung cancer currently under development. | Health Technology |
- Bourse
- Insiders
- Sylvie le Gledic
- Expérience